For citations:
Boiko AN, Zakharova MN, Simaniv TO, Alifirova VM, Arefieva EG, Barabanova MA, Goncharova ZA, Greshnova IV, Dorogov NV, Dudin VA, Korobko DS, Kotov SV, Mishin GN, Parshin EV, Poverennova IE, Pokhabov DV, Lebedev VM, Smagina IV, Spirin NN, Sivertseva SA, Totolyan NA, Khairutdinova DF, Trushnikova TN, Zaslavsky LG, Bakhtiyarova KZ, Prazdnichkova EV, Khabirov FA, Bunyak AG, Yakubtsevich RE, Tolkacheva DG, Sapozhnikov KV, Mironenko ON, Lazarev AA, Batorova VD, Krasnova MV, Porozova AA, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV. Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(4):16-25. (In Russ.) https://doi.org/10.14412/2074-2711-2025-4-16-25
Email this article 